Your browser is no longer supported. Please, upgrade your browser.
RETA Reata Pharmaceuticals, Inc. monthly Stock Chart
RETA [NASD]
Reata Pharmaceuticals, Inc.
Index- P/E- EPS (ttm)-4.06 Insider Own0.50% Shs Outstand29.60M Perf Week-2.22%
Market Cap6.02B Forward P/E- EPS next Y-6.54 Insider Trans-50.00% Shs Float22.21M Perf Month22.00%
Income-120.00M PEG- EPS next Q-1.24 Inst Own73.60% Short Float15.08% Perf Quarter168.60%
Sales29.20M P/S206.23 EPS this Y-46.00% Inst Trans-0.88% Short Ratio6.80 Perf Half Y122.05%
Book/sh-1.11 P/B- EPS next Y-1.90% ROA-35.30% Target Price219.50 Perf Year231.12%
Cash/sh9.47 P/C21.48 EPS next 5Y- ROE- 52W Range47.50 - 217.47 Perf YTD262.64%
Dividend- P/FCF- EPS past 5Y-10.60% ROI-82.50% 52W High-6.45% Beta2.73
Dividend %- Quick Ratio4.20 Sales past 5Y0.90% Gross Margin- 52W Low328.29% ATR14.36
Employees123 Current Ratio4.20 Sales Q/Q2.60% Oper. Margin- RSI (14)61.69 Volatility9.72% 6.45%
OptionableYes Debt/Eq- EPS Q/Q-6.10% Profit Margin- Rel Volume4.94 Prev Close187.48
ShortableYes LT Debt/Eq- EarningsNov 12 BMO Payout- Avg Volume492.60K Price203.44
Recom1.10 SMA203.47% SMA5052.33% SMA200107.61% Volume2,432,737 Change8.51%
Nov-13-19Downgrade National Securities Buy → Neutral
Sep-26-19Initiated National Securities Buy $130
Sep-25-18Reiterated Leerink Partners Outperform $116 → $139
Sep-13-17Initiated Leerink Partners Outperform $43
Jul-25-17Reiterated Citigroup Buy $39 → $87
Apr-13-17Initiated Ladenburg Thalmann Buy $55
Feb-23-17Initiated Stifel Buy $38
Jan-25-17Initiated Robert W. Baird Outperform $43
Jun-20-16Initiated Piper Jaffray Overweight $33
Jun-20-16Initiated Citigroup Buy
Nov-13-19 07:15PM  Reata Pharmaceuticals, Inc. Announces Pricing of Upsized Class A Common Stock Public Offering GlobeNewswire
Nov-12-19 04:01PM  Reata Pharmaceuticals, Inc. Announces Proposed Public Offering of Class A Common Stock GlobeNewswire -14.43%
07:55AM  Reata Pharmaceuticals, Inc. (RETA) Reports Q3 Loss, Tops Revenue Estimates Zacks
07:20AM  The Daily Biotech Pulse: Reata, Kadmon Clinical Readouts, Apyx Medical's Earnings Beat Benzinga
06:45AM  Reata Pharmaceuticals, Inc. Announces Third Quarter 2019 Financial Results and an Update on Development Programs GlobeNewswire
Nov-11-19 05:15PM  This Biotech Has Rocketed 181% Since October Did It Just Tap Out? Investor's Business Daily
04:23PM  Reata Pharma kidney drug meets study goals, stock halted MarketWatch
04:02PM  Reata Announces Positive Topline Year One Results From Pivotal Phase 3 Cardinal Study of Bardoxolone Methyl in Patients With Alport Syndrome GlobeNewswire
Nov-05-19 06:45AM  Reata Pharmaceuticals, Inc. to Report Third Quarter 2019 Financial Results and to Provide an Update on Development Programs on November 12, 2019 GlobeNewswire
Oct-30-19 10:33AM  Earnings Preview: Reata Pharmaceuticals, Inc. (RETA) Q3 Earnings Expected to Decline Zacks
Oct-29-19 01:37PM  Reata Pharmaceuticals, Inc. (RETA): These Hedge Funds Sold Prior To Large Gains Insider Monkey
Oct-20-19 08:08AM  The Week Ahead In Biotech: Earnings Trickle In, While Glaxo, Melinta, Foamix And Eton Await FDA Verdict Benzinga
Oct-17-19 08:58AM  Reata (RETA) Jumps: Stock Rises 5. 6% Zacks
Oct-16-19 07:06AM  The Daily Biotech Pulse: Akebia Sues CMS, Roche Raises Guidance Yet Again, Titan Medical Entangled In Credit Crunch Benzinga +5.60%
05:03AM  Riding 2 Big Winners in Small Biotech TheStreet.com
Oct-15-19 05:13PM  Reata Successfully Completes Neuromuscular Disorder Study Zacks +56.99%
04:13PM  How A Recently Reacquired Drug Added $1.8 Billion To This Biotech's Value Investor's Business Daily
01:13PM  A Look At Benzinga Pro's Most-Searched Tickers For October 15, 2019 Benzinga
10:10AM  Reata Pharmaceuticals Options Hot as Shares Skyrocket Schaeffer's Investment Research
07:50AM  The Daily Biotech Pulse: Reata Leaps On Positive Readout, Takeda Divests, FDA Nod For Akorn, J&J Earnings Benzinga
Oct-14-19 04:36PM  Reata stock jumps 30% as neuromuscular disorder drug meets study endpoint MarketWatch
04:01PM  Reata Announces Positive Topline Results from the MOXIe Registrational Trial of Omaveloxolone in Patients with Friedreichs Ataxia GlobeNewswire
01:52PM  [video]Reata Shares Jump on Drug-Study Results TheStreet.com
Oct-11-19 10:00AM  Reata Pharmaceuticals, Inc. Announces Presentations at the American Society for Nephrology Kidney Week 2019 GlobeNewswire +11.43%
Oct-10-19 04:18PM  Why This Biotech Stock Was Bullish Enough To Relicense Its Own Drugs Investor's Business Daily +13.00%
07:31AM  The Daily Biotech Pulse: UCB To Buy Ra Pharma, Reata Reacquires Rights To Nrf2 Activators From AbbVie, BioNTech IPO Benzinga
06:45AM  Reata Pharmaceuticals Reacquires Rights From AbbVie to Develop and Commercialize Bardoxolone Methyl, Omaveloxolone, and All Next-Generation Nrf2 Activators GlobeNewswire
Oct-01-19 07:22AM  Is Reata Pharmaceuticals, Inc.'s (NASDAQ:RETA) CEO Pay Fair? Simply Wall St. -5.98%
Sep-11-19 10:02AM  Is the Options Market Predicting a Spike in Reata Pharmaceuticals (RETA) Stock? Zacks
Sep-06-19 09:40AM  Is Reata Pharmaceuticals (NASDAQ:RETA) Using Debt Sensibly? Simply Wall St.
Sep-02-19 03:09PM  Edited Transcript of RETA earnings conference call or presentation 8-Aug-19 12:00pm GMT Thomson Reuters StreetEvents
Aug-29-19 07:38AM  The Daily Biotech Pulse: EC Approves Roche's Tecentriq For Breast Cancer, Trevena On Track For NDA Resubmission, Edap Earnings Benzinga +6.53%
Aug-28-19 04:01PM  Reata Appoints Manmeet S. Soni as Chief Financial Officer; Jason D. Wilson to Assume New Role as EVP, Operations GlobeNewswire
Aug-12-19 01:47AM  Reata Pharmaceuticals, Inc. (RETA) Q2 2019 Earnings Call Transcript Motley Fool
Aug-08-19 07:55AM  Reata Pharmaceuticals, Inc. (RETA) Reports Q2 Loss, Tops Revenue Estimates Zacks
06:40AM  Reata Pharmaceuticals, Inc. Announces Second Quarter 2019 Financial Results and an Update on Development Programs GlobeNewswire
Aug-01-19 11:49AM  Is Reata Pharmaceuticals, Inc.'s (NASDAQ:RETA) CEO Paid At A Competitive Rate? Simply Wall St.
06:45AM  Reata Pharmaceuticals, Inc. to Report Second Quarter 2019 Financials and to Provide an Update on Development Programs on August 8, 2019 GlobeNewswire
Jun-17-19 10:27AM  The Reata Pharmaceuticals (NASDAQ:RETA) Share Price Has Soared 359%, Delighting Many Shareholders Simply Wall St.
Jun-11-19 04:36PM  Hedge Funds Have Never Been This Bullish On Reata Pharmaceuticals, Inc. (RETA) Insider Monkey
Jun-06-19 10:29AM  Reata's (RETA) Kidney Candidate Gets Orphan Drug Status Zacks
07:37AM  The Daily Biotech Pulse: Takeda Pulls Plug On Amyloidosis Drug Trial, Chiasma Preps For Drug Launch With New CEO Appointment, Orchard Prices Offering Benzinga
Jun-05-19 06:00PM  Reata Pharmaceuticals, Inc. Receives Orphan Drug Designation for Bardoxolone Methyl for the Treatment of Autosomal Dominant Polycystic Kidney Disease GlobeNewswire
Jun-04-19 07:00PM  Reata Announces Presentations at the 56th Congress of the European Renal Association and European Dialysis and Transplant Association (ERA-EDTA) GlobeNewswire
May-30-19 06:45AM  Reata Announces First Patient Enrolled in Phase 3 FALCON Trial of Bardoxolone Methyl for the Treatment of Autosomal Dominant Polycystic Kidney Disease GlobeNewswire
May-23-19 01:47AM  Edited Transcript of RETA earnings conference call or presentation 9-May-19 12:00pm GMT Thomson Reuters StreetEvents -5.30%
May-22-19 12:46PM  Reata's drug, Bardoxolone, shows promising results for chronic kidney disease Yahoo Finance Video
May-09-19 08:23PM  Reata Pharmaceuticals, Inc. (RETA) Q1 2019 Earnings Call Transcript Motley Fool
07:55AM  Reata Pharmaceuticals, Inc. (RETA) Reports Q1 Loss, Lags Revenue Estimates Zacks
06:45AM  Reata Pharmaceuticals, Inc. Announces First Quarter 2019 Financial Results and an Update on Development Programs GlobeNewswire
May-06-19 03:26PM  Biotech developing kidney disease treatment jumps after hedge fund recommendation at conference CNBC +5.77%
May-02-19 04:15PM  Reata Announces Presentation at the Annual CKD3 Chronic Kidney Disease Drug Development Summit GlobeNewswire
06:45AM  Reata Pharmaceuticals, Inc. to Report First Quarter 2019 Financials and to Provide an Update on Development Programs on May 9, 2019 GlobeNewswire
May-01-19 12:45PM  Did Hedge Funds Drop The Ball On Reata Pharmaceuticals, Inc. (RETA) ? Insider Monkey
Apr-30-19 07:52AM  Reata Pharmaceuticals, Inc. (NASDAQ:RETA): When Will It Breakeven? Simply Wall St.
Apr-02-19 03:20PM  Reata CEO on drug that shows signs of reversing kidney damage CNBC Videos +7.29%
Mar-15-19 11:43AM  Edited Transcript of RETA earnings conference call or presentation 28-Feb-19 1:00pm GMT Thomson Reuters StreetEvents
Feb-28-19 11:56AM  Reata Pharmaceuticals, Inc. (RETA) Q4 2018 Earnings Conference Call Transcript Motley Fool
06:45AM  Reata Pharmaceuticals, Inc. Announces Fourth Quarter and Full Year 2018 Financials and Operating Results GlobeNewswire
Feb-25-19 12:59PM  Who Has Been Buying Reata Pharmaceuticals, Inc. (NASDAQ:RETA) Shares? Simply Wall St.
Feb-22-19 10:30AM  Analysts Estimate Reata Pharmaceuticals, Inc. (RETA) to Report a Decline in Earnings: What to Look Out for Zacks
Feb-21-19 06:45AM  Reata Pharmaceuticals, Inc. to Report Fourth Quarter and Full Year 2018 Financials and to Provide an Update on Development Programs GlobeNewswire
Feb-20-19 06:45AM  Reata Announces Positive Phase 2 Data for Bardoxolone Methyl in Patients with Focal Segmental Glomerulosclerosis and in Patients From All Four Cohorts of PHOENIX GlobeNewswire
Feb-05-19 07:45AM  Analysis: Positioning to Benefit within LPL Financial, The Andersons, Del Frisco's Restaurant Group, United Fire Group, Reata Pharmaceuticals, and Federal Agricultural Mortgage Research Highlights Growth, Revenue, and Consolidated Results GlobeNewswire
Jan-07-19 07:15AM  Reata Pharmaceuticals, Inc. Appoints Geoffrey A. Block, M.D. as Vice President, Nephrology GlobeNewswire +23.24%
Jan-04-19 09:02AM  2 Promising Biotech Stocks That Insiders Are Snapping Up TheStreet.com +13.74%
Jan-03-19 04:01PM  Reata Announces Clinical Trial Design for FALCON, a Phase 3 Trial of Bardoxolone Methyl for the Treatment of Autosomal Dominant Polycystic Kidney Disease GlobeNewswire -6.87%
Dec-19-18 01:17AM  Reata Pharmaceuticals, Inc. (RETA): Hedge Funds Are Snapping Up Insider Monkey
Nov-26-18 08:55AM  Report: Exploring Fundamental Drivers Behind Reata Pharmaceuticals, Calyxt, SIFCO Industries, EchoStar, Tel-Instrument Electronics, and United States Antimony New Horizons, Emerging Trends, and Upcoming Developments GlobeNewswire +6.68%
Nov-19-18 05:53PM  Edited Transcript of RETA earnings conference call or presentation 7-Nov-18 1:00pm GMT Thomson Reuters StreetEvents
Nov-07-18 11:20AM  Reata Pharmaceuticals, Inc. (RETA) Reports Q3 Loss, Lags Revenue Estimates Zacks +13.41%
07:00AM  Reata Pharmaceuticals, Inc. Announces Third Quarter 2018 Financial Results and an Update on Development Programs GlobeNewswire
Oct-31-18 04:35PM  Reata Pharmaceuticals, Inc. to Report Third Quarter 2018 Financial Results and Provide an Update on Development Programs on Wednesday, November 7, 2018 GlobeNewswire
Oct-16-18 07:05AM  Reata Announces Presentation of Four Clinical Abstracts at the American Society of Nephrology Kidney Week 2018 GlobeNewswire
Oct-09-18 07:40AM  Research Report Identifies Cerner, Reata Pharmaceuticals, Lennar, Acacia Communications, GoPro, and ProAssurance with Renewed Outlook Fundamental Analysis, Calculating Forward Movement GlobeNewswire
Sep-25-18 07:00AM  Reata Announces Positive Phase 2 Data for Bardoxolone Methyl in IgA Nephropathy and Type 1 Diabetic Chronic Kidney Disease GlobeNewswire
Sep-21-18 08:58AM  Is the Options Market Predicting a Spike in Reata Pharmaceuticals (RETA) Stock? Zacks
Sep-18-18 08:24AM  Who Just Ramped Up Their Shares In Reata Pharmaceuticals Inc (NASDAQ:RETA)? Simply Wall St.
Aug-30-18 06:40PM  Reata Announces Receipt of $30 Million Milestone Payment From Kyowa Hakko Kirin GlobeNewswire
Aug-22-18 11:41AM  Edited Transcript of RETA earnings conference call or presentation 8-Aug-18 8:30pm GMT Thomson Reuters StreetEvents
Aug-08-18 08:05PM  Reata Pharmaceuticals, Inc. (RETA) Reports Q2 Loss, Lags Revenue Estimates Zacks
04:01PM  Reata Pharmaceuticals, Inc. Announces Second Quarter 2018 Financial Results and an Update on Development Programs GlobeNewswire
Aug-06-18 05:35PM  Reata Pharmaceuticals, Inc. to Report Second Quarter 2018 Financial Results and an Update on Development Programs on Wednesday, August 8, 2018 GlobeNewswire
Jul-28-18 08:38AM  3 Healthcare Stocks That Skyrocketed 35% or More This Week: Are They Still Buys? Motley Fool
Jul-27-18 11:05AM  Reata Pharmaceuticals, Inc. Announces Closing of Class A Common Stock Public Offering and Full Exercise of Underwriters Option to Purchase Additional Shares GlobeNewswire
Jul-25-18 08:30AM  Investor Expectations to Drive Momentum within Reata Pharmaceuticals, Shoe Carnival, United Fire Group, Approach Resources, Saul Centers, and Tennant Discovering Underlying Factors of Influence GlobeNewswire
Jul-24-18 08:52PM  Reata Pharmaceuticals, Inc. Announces Pricing of Class A Common Stock Public Offering GlobeNewswire
12:40PM  These Biotech Stocks Should Be On Your Watch-List ACCESSWIRE
08:00AM  Todays Research Reports on Stocks to Watch: Reata Pharmaceuticals and LifePoint Health ACCESSWIRE
Jul-23-18 04:57PM  Here's Why Reata Pharmaceuticals Skyrocketed 65% Today Motley Fool +64.98%
04:39PM  Reata Pharmaceuticals, Inc. Announces Proposed Public Offering of Class A Common Stock GlobeNewswire
06:45AM  Reata Announces Positive Phase 2 Data for Bardoxolone Methyl in CKD Caused by Alport Syndrome and Autosomal Dominant Polycystic Kidney Disease GlobeNewswire
Jul-17-18 09:38AM  Can The Uptrend Continue for Reata Pharmaceuticals (RETA)? Zacks
Jul-10-18 04:18PM  Reata Receives Orphan Drug Designation from the European Commission for Omaveloxolone for the Treatment of Friedreichs Ataxia GlobeNewswire
Jun-20-18 04:18PM  Reata Announces Initiation of a Phase 1 Trial of RTA 1701, a Selective, Oral Allosteric Inhibitor of RORt GlobeNewswire
Jun-14-18 04:15PM  Reata Pharmaceuticals, Inc. Secures $125 Million Term Loan Facility GlobeNewswire
Jun-04-18 07:30AM  Reata Announces That Kyowa Hakko Kirin Initiated Ayame, a Phase 3 Trial of Bardoxolone Methyl for the Treatment of Diabetic Kidney Disease GlobeNewswire
Jun-01-18 04:15PM  Reata Selected to Present Early-Stage Programs at the BIO International Convention GlobeNewswire
08:16AM  Benzinga's Daily Biotech Pulse: Organovo Falls On Earnings; Celgene Gets New CFO Benzinga
May-31-18 04:15PM  Reata Announces Orphan Drug Designation From the European Commission for Bardoxolone Methyl for the Treatment of Alport Syndrome GlobeNewswire
Reata Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops novel therapeutics for patients with serious or life-threatening diseases by targeting molecular pathways that regulate cellular metabolism and inflammation. The company is developing Phase III clinical trial programs, including bardoxolone methyl (Bard) for the treatment of patients with chronic kidney disease caused by Alport syndrome, as well as for a form of pulmonary arterial hypertension associated with connective tissue disease; and omaveloxolone that is Phase II clinical trial for the treatment of patients with Friedreich's ataxia It is also developing RTA 901, which completed Phase 1 clinical trials for the treatment of orphan neurological indications; and RORgT Inhibitors that are in the preclinical development phase for the potential treatment of a range of autoimmune, inflammatory, and fibrotic diseases. Reata Pharmaceuticals, Inc. has a strategic collaboration agreement with Kyowa Hakko Kirin Co., Ltd. to develop and commercialize Bard for renal, cardiovascular, diabetes, and various other related metabolic indications in Japan, China, Hong Kong, Macao, South Korea, Taiwan, Thailand, Singapore, the Philippines, Malaysia, Indonesia, Brunei, Vietnam, Laos, Myanmar, and Cambodia; and AbbVie Inc. to jointly research, develop, and commercialize all second- and later-generation Nrf2 activators for all indications other than renal, cardiovascular, and metabolic indications. The company was formerly known as Reata Discovery, Inc. and changed its name to Reata Pharmaceuticals, Inc. in May 2005. Reata Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Irving, Texas.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Castellanos ElaineVP, Chief Accounting OfficerOct 28Sale200.004,000800,00015,146Oct 30 11:32 AM
Castellanos ElaineVP, Chief Accounting OfficerOct 25Sale190.002,000380,00015,146Oct 28 04:41 PM
Castellanos ElainePrincipal Accounting OfficerOct 18Sale170.002,000340,00011,933Oct 21 03:32 PM
Wilson Jason DouglasExecutive VP of OperationsOct 17Sale170.0010,0001,700,0007,350Oct 21 03:39 PM
Castellanos ElainePrincipal Accounting OfficerOct 15Sale147.5914,0002,066,24011,933Oct 17 04:51 PM
Wilson Jason DouglasExecutive VP of OperationsOct 15Sale146.1315,0002,191,9567,350Oct 15 04:03 PM
Wilson Jason DouglasExecutive VP of OperationsOct 14Sale100.0015,0001,500,0007,350Oct 15 04:03 PM
Castellanos ElainePrincipal Accounting OfficerOct 14Sale105.003,000315,00011,933Oct 15 03:52 PM
Huff James WarrenChief Executive OfficerSep 27Sale86.6163,0005,456,11594,157Sep 30 03:18 PM
Castellanos ElainePrincipal Accounting OfficerSep 06Sale85.002,000170,0002,138Sep 10 03:46 PM
Wilson Jason DouglasChief Financial OfficerAug 15Sale72.684,000290,7350Aug 16 03:09 PM
Wilson Jason DouglasChief Financial OfficerJul 15Sale84.644,000338,5560Jul 17 01:01 PM
Wilson Jason DouglasChief Financial OfficerJun 17Sale83.544,000334,1770Jun 19 04:06 PM
Castellanos ElainePrincipal Accounting OfficerJun 03Sale85.202,000170,4002,138Jun 05 01:10 PM
Wilson Jason DouglasChief Financial OfficerMay 15Sale89.914,000359,6310May 17 11:47 AM
Wilson Jason DouglasChief Financial OfficerApr 15Sale83.824,000335,2620Apr 16 02:21 PM
Castellanos ElainePrincipal Accounting OfficerApr 08Sale90.172,000180,3402,138Apr 09 05:24 PM
Wilson Jason DouglasChief Financial OfficerMar 19Sale93.5128,3962,655,2090Mar 21 03:23 PM
Wilson Jason DouglasChief Financial OfficerMar 18Sale95.111,604152,5560Mar 19 05:32 PM
Wilson Jason DouglasChief Financial OfficerMar 15Sale93.624,000374,4700Mar 19 05:32 PM
WORTLEY MICHAEL DChief Legal OfficerMar 05Sale100.1626,9402,698,4410Mar 07 05:22 PM
Castellanos ElainePrincipal Accounting OfficerMar 05Sale102.003,588365,9762,138Mar 07 05:12 PM
Bass James EdwardDirectorMar 05Sale100.295,852586,92011,703Mar 07 05:05 PM
Ward Keith WayneChief Development OfficerFeb 26Sale91.2125,1842,296,9328,620Feb 27 04:22 PM
Ward Keith WayneChief Development OfficerFeb 25Sale91.0015,1831,381,6538,620Feb 27 04:22 PM
Wilson Jason DouglasChief Financial OfficerFeb 15Sale85.444,000341,7600Feb 19 01:50 PM
Wilson Jason DouglasChief Financial OfficerFeb 05Sale80.003,000240,0000Feb 06 01:01 PM
Ward Keith WayneChief Development OfficerJan 31Sale76.704,150318,3028,620Feb 01 11:50 AM
Wilson Jason DouglasChief Financial OfficerJan 15Sale71.154,000284,5890Jan 16 04:26 PM
Wilson Jason DouglasChief Financial OfficerJan 07Sale72.0420,0001,440,8200Jan 09 04:43 PM
Ward Keith WayneChief Development OfficerJan 02Sale53.994,150224,0450Jan 03 02:45 PM
Bass James EdwardDirectorDec 20Buy52.1288846,28754,110Dec 21 09:45 AM
Traweek James W JR10% OwnerDec 12Buy59.901,41884,9313,023,349Dec 12 05:59 PM
CPMG IncDirectorDec 12Buy59.901,41884,931281,918Dec 12 05:57 PM
McGaughy R Kent JrDirectorDec 12Buy59.901,41884,9313,023,349Dec 12 05:58 PM
Traweek James W JR10% OwnerDec 11Buy60.0752,8093,172,3373,021,931Dec 12 05:59 PM
CPMG IncDirectorDec 11Buy60.0752,8093,172,337109,408Dec 12 05:57 PM
McGaughy R Kent JrDirectorDec 11Buy60.0752,8093,172,3373,021,931Dec 12 05:58 PM
Traweek James W JR10% OwnerDec 10Buy58.7756,5993,326,5662,969,122Dec 12 05:59 PM
CPMG IncDirectorDec 10Buy58.7756,5993,326,56656,599Dec 12 05:57 PM
McGaughy R Kent JrDirectorDec 10Buy58.7756,5993,326,5662,969,122Dec 12 05:58 PM
Bass James EdwardDirectorNov 16Buy59.331,67999,61553,222Nov 19 11:57 AM